CVS Health Corp said on Saturday, September 28 that it will stop sales of the popular drug Zantac, which is struggling with reflux, and their own generic drugs ranitidine at their pharmacies once in some products had traces of a known carcinogen, said the Management on control over products and medicines of the USA.
Earlier this month, the FDA announced that some tablets contain a small amount of N-nitrosodimethylamine (NDMA), which was also discovered in some widely used cures for blood pressure, which led to shortages of these drugs.
CVS stated that the decision to suspend sales of drugs from heartburn that is sold without a prescription, was taken with caution, as the FDA continues to analyze whether the low level NDMA ranitidine, the active ingredient, which causes a risk to the health of patients.
“Products of the brand and products Zantac ranitidine CVS brand was not recalled and the FDA recommends that patients not stop taking the ranitidine at this time”, – said in a statement.
Last week, the division of Sandart in Novartis AG announced that it would stop the spread of Zantac on all of its markets, including the United States and Canada after the security check of the American and European drug regulators.